6日，A股三大指数高开，截至9：50左右，沪指报4054.25点，突破2025年11月14日的阶段高点，刷新2015年7月底以来的新高。 | 上证指数 | 深证成指 | 科创综指 | | --- | --- | --- | | 4054.25 | 13946.42 | 1723.70 | | +30.83 +0.77% +117.79 +0.85% +27.86 +1.64% | | | | 万得全A | 创业板指 | 北证50 | | 6599.79 | 3318.62 | 1482.88 | | +61.85 +0.95% +24.07 +0.73% +16.46 +1.12% | | | | 沪深300 | 中证500 | 中证A500 | | 4762.71 | 7745.80 | 5823.89 | | +44.97 +0.95% | +94.61 +1.24% +60.59 +1.05% | | | 中证1000 | 深证100 | 中证红利 | | 7818.17 | 5966.20 | 5538.87 | | +64.29 +0.83% | +37.87 +0.64% | +13.75 +0. ...

Core Viewpoint - The offshore RMB has fallen below the 6.98 mark against the US dollar, with Citigroup predicting that the RMB exchange rate will rise to 6.8 in the next 6-12 months, enhancing the attractiveness of Hong Kong stocks for foreign investors [1] Group 1: Currency and Market Dynamics - The depreciation of the RMB is expected to lead to increased foreign capital inflow into the Hong Kong stock market [1] - Southbound capital has continued its net inflow trend after the New Year, with a net purchase exceeding 18.7 billion HKD on January 5 [1] - For the entire year of 2025, over 1.4 trillion HKD in southbound capital is anticipated to provide strong liquidity support for the Hong Kong stock market [1] Group 2: AI Industry Performance - The AI industry chain remains active, with companies like SenseTime, JD Health, and Tongcheng Travel showing significant gains [1] - The Hang Seng Tech Index experienced a substantial increase, with intraday gains exceeding 2% [1] - The largest Hang Seng Tech Index ETF (513180) saw active trading [1]

Market Overview - The A-share market showed mixed performance on January 6, with the Shanghai Composite Index rising over 1% to reach a ten-year high, closing up 1.14% at 4069.38 points [1][2] - The Shenzhen Component Index increased by 0.81%, while the ChiNext Index slightly declined by 0.04% [1][2] Sector Performance - The precious metals, chemicals, and large financial sectors experienced significant gains, while sectors such as communication equipment, optical modules, and motorcycles faced notable declines [2][10] - The non-ferrous metals sector strengthened again, with industrial metals like copper and aluminum leading the gains; Zijin Mining's stock rose over 6%, reaching a historical high with a market capitalization exceeding 100 billion [6] Notable Stocks - In the Hong Kong market, the Hang Seng Technology Index rose over 2%, with companies like JD Health, SenseTime, and NetEase showing significant gains [4] - JD Health's stock price increased by 6.44%, with a market cap of 198.8 billion; SenseTime rose by 6.70% to a market cap of 96.6 billion; NetEase increased by 4.04% with a market cap of 733.7 billion [5] Chemical Sector Insights - The chemical sector saw a rally, particularly in the salt chemical direction, with stocks like Chlor-Alkali Chemical and Bofei Electric reaching their daily limit [10][11] - PVC futures rose over 3% in a single day, with a cumulative increase of over 15% since mid-December [11][12] - Wanhua Chemical announced a price increase for core products like MDI/TDI starting December 2025, aligning with international giants, driven by rising raw material costs and industry-wide maintenance [12]

Market Overview - The A-share market showed mixed performance on January 6, with the Shanghai Composite Index rising over 1% to reach a ten-year high, closing at 4069.38, up 1.14% [2][3] - The trading volume reached 1.80 trillion CNY, with a predicted total of 2.82 trillion CNY, an increase of 249.7 billion CNY [3] Sector Performance - The non-ferrous metals, chemical, and large financial sectors experienced strong upward movements, while sectors like communication equipment and motorcycles saw significant declines [4][16] - The non-ferrous metals sector, particularly copper and aluminum, led the gains, with Zijin Mining's stock price rising over 6%, reaching a historical high and a market capitalization exceeding 1 trillion CNY [9][11] Chemical Sector Insights - The chemical sector also saw a notable rise, particularly in the salt chemical segment, with several stocks hitting the daily limit [17] - PVC futures rose over 3% in a single day, accumulating a rise of over 15% since mid-December [19] - Wanhua Chemical announced price increases for core products starting December 2025, aligning with international giants like BASF and Dow, driven by rising raw material costs [20] Notable Stocks - Zhite New Materials surged by 20%, while other stocks like Liyuan Co., Chang Aluminum, and Anning Co. also hit the daily limit [11] - In the chemical sector, stocks such as Dongyue Yicai and Chlor-Alkali Chemical saw increases of over 10% [18] Precious Metals Market - Domestic precious metals futures continued to rise, with silver and platinum contracts increasing by over 7% [13] - The price of gold jewelry in China rose to 1390 CNY per gram, an increase of 12 CNY from the previous day [13]

Market Overview - The A-share market showed mixed performance with the Shanghai Composite Index rising over 1%, reaching a ten-year high, while the Shenzhen Component Index increased by 0.81% and the ChiNext Index slightly declined by 0.04% [1] - The Hong Kong market saw the Hang Seng Technology Index rise over 2%, with notable gains from JD Health, SenseTime, and NetEase [1] Sector Performance Non-ferrous Metals - The non-ferrous metals sector strengthened, with industrial metals like copper and aluminum leading the gains. Zijin Mining's stock surged over 6%, hitting a historical high with a market capitalization exceeding 1 trillion yuan [4] - Other stocks such as Zhite New Materials and Liyuan Co. also reached their daily limit up [4] Precious Metals - Domestic precious metals futures continued to rise, with silver and platinum contracts increasing by over 7%. The price of gold jewelry also saw an uptick, with prices for 24K gold jewelry reported at 1390 yuan per gram, up by 12 yuan from the previous day [6][8] Chemical Sector - The chemical sector experienced a rally, particularly in the salt chemical segment, with stocks like Chlor-Alkali Chemical and Bofei Electric hitting their daily limit up [9] - PVC futures rose over 3% in a single day, accumulating a rise of over 15% since mid-December [11] - Wanhua Chemical announced a price increase for core products starting December 2025, aligning with international giants like BASF and Dow, driven by rising raw material costs and industry-wide maintenance [12] - The chemical industry is expected to benefit from a recovery in supply-demand dynamics, with a projected upward cycle in industry prosperity due to policies aimed at reducing competition [12]

每经AI快讯，京东健康(06618.HK)午前涨超6%，截至发稿涨6.53%，报62港元，成交额4.11亿港元。 （文章来源：每日经济新闻） ...

Core Viewpoint - JD Health (06618) is expected to outperform market expectations in the second half of 2025, driven by a surge in flu cases leading to increased demand for pharmaceuticals [1] Group 1: Financial Performance - JD Health's stock rose over 6%, reaching HKD 62 with a trading volume of HKD 411 million [1] - Nomura forecasts that JD Health's revenue for Q4 2025 will reach RMB 20 billion, representing a year-on-year growth of 22% [1] - The growth in Q4 2025 is attributed to sales increases in pharmaceuticals (30%), nutritional products (20%), and medical devices (10%) [1] Group 2: Market Trends - The increase in flu cases in Q4 2025 is expected to significantly boost pharmaceutical sales, contributing a high single-digit percentage to total sales [1] - The sales of medical devices, such as home oxygen concentrators, are also anticipated to rise due to the flu season [1] - Nutritional brands will continue effective marketing campaigns in Q4 2025, reinforcing their growth trajectory [1] Group 3: Strategic Partnerships - CICC noted strong revenue performance for JD Health in 2025, with quarterly growth rates around 25% year-on-year for Q1 to Q3 [1] - The company has signed strategic cooperation agreements with pharmaceutical companies like Eli Lilly, Innovent Biologics, and Bayer China, enhancing its unique business model of launching new drugs online [1] - The ongoing trend of increasing original drug volumes is expected to support strong revenue performance in Q4 2025 [1]

Core Viewpoint - JD Health is expected to outperform market expectations in the second half of 2025, primarily due to a surge in flu cases driving up demand for pharmaceuticals [1] Group 1: Financial Performance - JD Health's revenue for Q4 2025 is projected to reach 20 billion RMB, representing a year-on-year growth of 22%, driven by sales growth in pharmaceuticals, nutritional products, and medical devices at 30%, 20%, and 10% respectively [1] - The company has shown strong revenue performance throughout 2025, with each quarter from Q1 to Q3 achieving approximately 25% year-on-year growth [1] - The overall revenue growth for JD Health in 2025 is anticipated to be close to 25% year-on-year [1] Group 2: Market Dynamics - The increase in flu cases in Q4 2025 is expected to significantly contribute to pharmaceutical sales, accounting for a high single-digit percentage of total pharmaceutical revenue [1] - The sales of medical devices, such as home oxygen concentrators, are also expected to rise due to the flu outbreak [1] - JD Health's nutritional brands will continue to implement effective marketing strategies in Q4 2025, reinforcing their growth trajectory [1] Group 3: Strategic Partnerships - JD Health has signed strategic cooperation agreements with pharmaceutical companies such as Eli Lilly, Innovent Biologics, and Bayer China, enhancing its business model of launching new drugs online [1]

消息面上，野村发表报告，预计京东健康2025年下半年业绩将好过市场预期，主要因2025年第四季流感 病例激增带动药品需求上升。该机构预估京东健康2025年第四季营收将达200亿元人民币，按年增长 22%，受惠来自药品/营养品/医疗器材业务分别实现30%、20%及10%按年销售增长。2025年第四季流感 病例扩散带动相关药品，占药品销售额高单位数百分比，及医疗设备如家用氧气浓缩机销售。与此同 时，营养品牌在2025年第四季持续推行有效营销活动，强化其稳健增长态势。 中金发布研报称，考虑到原研品类放量趋势依旧且流感品种需求强劲，上调京东健康25年及26年收入预 测2%至725亿元及817亿元，同时考虑毛利率改善趋势及潜在利息收入波动的综合影响，该行分别上调 25年及26年non-IFRS净利润4%及1%至65亿元及64亿元。首次引入27年收入预测912亿元及non-IFRS净 利润预测68亿元。考虑到近期板块表现略有波动，基于SOTP维持目标价71.4港币不变(23%上行空间)， 维持跑赢行业评级。 金吾财讯 | 京东健康(06618)股价上行，截至发稿，涨5.58%，报61.45港元，成交额2.3亿港元。 消息 ...

Investment Rating - The report maintains a "Buy" rating for JD Health with a target price of HKD 77.40 [7][18]. Core Insights - JD Health is expected to continue strong revenue growth in 4Q25, with a projected year-on-year increase of 22.7% to RMB 20.26 billion, driven by the increasing online penetration of pharmaceuticals and the company's competitive advantages in supply chain management [2][15]. - The company is anticipated to achieve a non-IFRS operating profit of RMB 260 million in 4Q25, reflecting a non-IFRS operating profit margin of 1.3%, an improvement of 0.4 percentage points year-on-year [2]. - The report highlights the importance of monitoring the supply iteration of new medical products, the impact of weight-loss drugs entering the medical insurance list, the penetration of AI medical applications, and the expansion of JD Health's O2O business [1]. Revenue and Profit Forecast - JD Health's total revenue for 4Q25 is expected to grow by 22.7% year-on-year to RMB 20.26 billion, with pharmaceuticals projected to see over 30% growth in GMV [2][15]. - For the full year of 2025, revenue is forecasted to increase by 25% to RMB 72.7 billion, with a non-IFRS operating profit of RMB 4.11 billion, corresponding to a non-IFRS operating profit margin of 5.7%, an improvement of 1.2 percentage points year-on-year [2][15]. Offline Business Development - JD Health is set to open over 200 new offline pharmacy stores in the second half of 2025, with 150 stores expected to open in 4Q25, enhancing user reach and brand exposure [3]. - The company's medical insurance payment coverage has expanded to 8 cities, including Shanghai, which is anticipated to drive user penetration and performance growth [3]. New Product Launches and AI Integration - JD Health continues to strengthen partnerships with upstream medical brands, achieving multiple collaborations for new drug launches, thereby enhancing its channel value [4]. - The report notes the positive reception of JD Health's AI doctor, which has achieved a satisfaction rate of 98%, reinforcing its capabilities in internet medical services [4]. Profitability Adjustments - The profit forecasts for 2025-2027 have been raised by 11.6%, 15.6%, and 22.4% respectively, due to improved revenue expectations and the anticipated release of operating leverage [5][15]. - The target valuation for 2026 has been adjusted to a non-IFRS PE of 30.0x, reflecting a premium over comparable companies, driven by JD Health's efficiency in the pharmaceutical market and its advantages in AI medical applications [18].